46 / 74 · 0:57 · Original AXON film
Retatrutide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Three receptor systems
Retatrutide acts at three receptor systems: GIP, GLP-1, and glucagon. The number of targets describes its design, not an automatic advantage over another medicine. [1]
2023 phase 2 | 338 adults
Its 2023 phase two trial randomly assigned 338 adults to retatrutide or placebo. Researchers measured body-weight change and recorded safety outcomes over 48 weeks. [1]
Weight and safety outcomes
Treated groups showed greater weight reduction. Gastrointestinal adverse events were common, and increases in heart rate were also observed during the study. [1]
Historical study, bounded conclusions
This early trial helped guide further research. Comparisons with other drugs require matched clinical evidence, and a weight-loss result alone does not settle long-term benefit or safety. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Jastreboff et al. (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial →Three receptor targets, 338 participants, 48-week study, weight outcomes, gastrointestinal events, and heart-rate changes.
